EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The PLCG2 Inhibits Tumor Progression and Mediates Angiogenesis by VEGF Signaling Pathway in Clear Cell Renal Cell Carcinoma

Chuanyi Zhao, Daojia Miao, Diaoyi Tan, Jian Shi, Qingyang Lv, Zhiyong Xiong, Xiaoping Zhang

Frontiers in Bioscience-Landmark · 2024

DOI: 10.31083/j.fbl2911390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Chuanyi Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Neovascularization, Pathologic, Signal Transduction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hubei Provincial Natural Science Foundation Projects, Wuhan Yingcai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clear cell renal cell carcinoma (ccRCC) represents the most prevalent form of renal cell carcinoma. The management of early-stage ccRCC has a better prognosis, while patients with metastatic ccRCC have a lower five-year survival rate. Angiogenesis serves as the fundamental process underlying tumor metastasis. Therefore, it is crucial to discover new targets for angiogenesis to improve patient survival rates.

Methods

The Cancer Genome Atlas database, International Cancer Genome Consortium database, Clinical Proteomic Tumor Analysis Consortium database, and a gene set of the vascular endothelial growth factor (VEGF) signaling pathway were utilized to identify differentially expressed genes. Western blot (WB), quantitative real-time polymerase chain reaction, and immunohistochemistry were employed to validate the downregulation of phospholipase C gamma 2 (PLCG2) in ccRCC tissues and cells. Cell Counting Kit-8 (CCK-8) assays, transwell assays, tube formation assays, and oil-red staining were performed to elucidate the biological functions of PLCG2 in tumor cells. Gene set enrichment analysis was applied to explore the downstream pathway. Subcutaneous tumor models and live small animal fluorescent imaging assay were utilized for in vivo investigation of the roles played by PLCG2.

Results

Our study has identified a novel biomarker, PLCG2, for ccRCC. PLCG2 is a central gene in regulating angiogenesis in ccRCC, as validated by bioinformatics analysis. The findings revealed a diminished expression of PLCG2 in both ccRCC tissues and cells. Further experiments in vivo and in vitro have demonstrated the significant roles of PLCG2 in tumor proliferation, invasion, migration, and lipid accumulation. Results of tube formation assays and WB support the role of PLCG2 in regulating VEGFA expression and angiogenesis.

Conclusions

Our results show that PLCG2 functions as a potential biomarker and an independent prognostic indicator for ccRCC. PLCG2 may modulate angiogenesis by influencing the expression of VEGFA. Therefore, targeting PLCG2 could potentially lead to drug discovery and improved cancer treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsNeovascularization, PathologicSignal TransductionVascular Endothelial Growth Factor APhospholipase C gammaHumansAnimalsCell Line, TumorGene Expression Regulation, NeoplasticDisease ProgressionMiceCell ProliferationMice, NudeMaleCell MovementFemaleAngiogenesis

Stichwörter der Autor:innen

PLCG2VEGF signaling wayangiogenesisclear cell renal cell carcinomametastasis

Substanzen

Vascular Endothelial Growth Factor APhospholipase C gammaVEGFA protein, human

Autor:innen und Institutionen

  • Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China.
  • Institute of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China.

Förderung

  • National Natural Science Foundation of China
  • Hubei Provincial Natural Science Foundation Projects
  • Wuhan Yingcai

Zitieren

APA

Zhao, C., Miao, D., Tan, D., Shi, J., Lv, Q., Xiong, Z., & Zhang, X. (2024). The PLCG2 Inhibits Tumor Progression and Mediates Angiogenesis by VEGF Signaling Pathway in Clear Cell Renal Cell Carcinoma. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2911390

Vancouver

Zhao C, Miao D, Tan D, Shi J, Lv Q, Xiong Z, et al. The PLCG2 Inhibits Tumor Progression and Mediates Angiogenesis by VEGF Signaling Pathway in Clear Cell Renal Cell Carcinoma. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2911390

BibTeX
@article{Zhao2024,
  author = {Zhao, Chuanyi and Miao, Daojia and Tan, Diaoyi and Shi, Jian and Lv, Qingyang and Xiong, Zhiyong and Zhang, Xiaoping},
  title = {The PLCG2 Inhibits Tumor Progression and Mediates Angiogenesis by VEGF Signaling Pathway in Clear Cell Renal Cell Carcinoma},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2024},
  doi = {10.31083/j.fbl2911390}
}
Kostenlos starten →